Alibaba is banning Claude Code after security researchers found hidden tracking code inside Anthropic’s tool designed to detect Chinese users, while Anthropic says the code was an anti-abuse experiment that has since been removed.
Amazon will stop accepting new customers for Mechanical Turk on July 30, 2026, effectively killing the platform that once employed thousands to label data and train the AI that now makes that labor unnecessary.
The Silicon Data LLM Token Expenditure Index dropped nearly 20% from its May high. Bloomberg flagged the decline as the industry questions whether AI infrastructure spending will ever generate the returns expected.
South Korea announced 1,350 trillion won ($880 billion) in AI and semiconductor investment from Samsung, SK Hynix, and major conglomerates, targeting 18+ gigawatts of AI data center capacity and four new chip fabs.
Operatives linked to Alibaba’s Qwen AI lab used 25,000 fraudulent accounts to run 28.8 million interactions with Claude between April and June 2026, extracting its knowledge to train a rival model. Anthropic is now closing the loopholes.
Anthropic hired UK law firm Freshfields as IPO adviser. Crunchbase H1 2026: global VC hit a record $510 billion with OpenAI and Anthropic alone absorbing $217 billion, 43% of all startup capital raised globally.
Axios revealed the full behind-the-scenes account: Andy Jassy called Treasury Secretary Bessent, not a national security official. Anthropic flew engineers to DC, NSA rejected their first fixes, and other models had the same vulnerability the whole time.
Grok 5 is still in training on Colossus 2 at 1.5 GW. Polymarket gave it 3% odds of a Q3 release. No timeline from xAI, no public benchmarks, and no competition for Fable 5 or GPT-5.6 Sol yet.
OpenAI confirmed GPT-5.6 Sol/Terra/Luna preview details. Terra delivers GPT-5.5-competitive performance at 2x lower cost, putting it directly against Claude Sonnet 5 in a genuine frontier AI price war.
Anthropic launched Claude Science, a research workbench with 60+ preconfigured tools for scientists, and announced an internal drug discovery program targeting neglected diseases no pharmaceutical company will fund.